Aastrinz Life Sciences: Building an Indian Chromatography Brand Around Quality, Expertise and Trust

Er. Aryan Batra, Managing Director

Er. Aryan Batra

Managing Director

Precision has always been fundamental to analytical science. Today, laboratories are being asked to deliver more than accurate results. Pharmaceutical, biotechnology, food, chemical and research organizations are looking for faster analysis, reproducible outcomes, greater automation, regulatory readiness and efficient workflows. This shift is strengthening demand for technologies such as high-performance liquid chromatography (HPLC), where advances in column chemistries, UHPLC and intelligent laboratory systems are improving analytical performance and throughput. According to Fortune Business Insights, the global HPLC market was valued at $5.36 billion in 2025 and is projected to reach $9.13 billion by 2034.

Within this evolving landscape, Aastrinz Life Sciences is positioning itself as an Indian chro­matography and analytical laboratory solutions company combining product quality with ap­plication expertise and responsive technical support. Its portfolio spans HPLC systems and columns, syringe filters, laboratory consumables, sample preparation solutions and analytical laboratory equipment. At the centre of its strategy is PURSIL, its HPLC col­umn brand, around which Aastrinz is building a broader chromatography ecosystem for pharmaceutical QC and R&D, chemicals, food testing, healthcare, clinical labo­ratories and research institutions.

“Rather than pursuing an expansive catalogue across unrelated laboratory categories, Aastrinz is taking a focused approach: deepen its chromatography capabilities, understand application-level challenges and build long term customer relationships through technical support”, speaks Er. Aryan Batra, Managing Director. 

Closing a Critical Gap in Laboratory Solutions

The origins of Aastrinz Life Sciences can be traced to a practical problem its founders observed within the pharmaceutical industry. With experience in pharmaceutical procurement and laboratory quality products, including HPLC columns and consumables, the founding team saw laboratories depending considerably on international chromatography brands. Customers could encounter cost pressures, long delivery timelines and limited technical assistance once a product had been supplied.

Amit Wadhwa has been an important part of the company’s founding journey and has contributed to the foundation and growth of Aastrinz Life Sciences. The company was conceived to address market gaps through a focused chromatography proposition backed by accessible technical expertise and closer customer engagement.

Building credibility in a technically demanding segment was essential. Pharmaceutical QC and R&D laboratories are understandably cautious when adopting new chromatography products because consistency and reproducibility directly affect analytical outcomes.

“Aastrinz addressed this barrier by allowing customers to evaluate trial columns and by developing an in-house laboratory capability in Hyderabad. Where required, customers can provide samples for evaluation, enabling the company to conduct testing and share relevant HPLC and chromatographic results”, shares Rajasekhar Reddy, Managing Director.

This in-house application and testing facility remains an important differentiator, allowing customers to evaluate products against their analytical requirements rather than relying solely on product claims.

Making PURSIL the Core of a Chromatography Ecosystem

Chromatography remains the strategic centre of Aastrinz’s business, with PURSIL HPLC Columns serving as one of its flagship offerings. For an HPLC column, performance is ultimately measured by what happens repeatedly inside the laboratory. A column must deliver dependable separation, consistent peak characteristics and reproducibility across analytical runs.

PURSIL HPLC Columns are manufactured under the technical guidance of G. Rambabu, whose manufacturing and technical expertise supports the development of the column portfolio. Aastrinz places emphasis on silica quality, consistency and application suitability while continuing to expand PURSIL for different analytical requirements.

Its R&D efforts have resulted in offerings across multiple column categories and chemistries, including general-purpose and phenyl segments. An important development within the portfolio is CoroShield Technology (CST), which forms part of Aastrinz’s efforts to expand PURSIL through specialized column technologies for evolving analytical requirements.

The company’s chromatography strategy extends beyond columns. Sample preparation can substantially affect analytical reliability, as contaminants and particulates entering an HPLC system may influence results and compromise columns and other system components.

“Aastrinz consequently considers syringe filtration an integral part of its chromatography proposition. Our syringe filter portfolio is designed to support cleaner sample preparation, system protection and analytical reliability, with the company focusing on features including multi-layer filtration and supporting quality documentation”, shares Aryan Batra.

Other complementary categories include filtration products, safety caps and solvent-management solutions. The objective is to progressively create a connected portfolio around chromatography rather than become a general-purpose supplier across unrelated laboratory categories.

Competing Through Technical Depth, Not Just Products

The analytical instruments business is fundamentally different from conventional product distribution. Supplying the right specification is only the beginning; customers frequently require assistance with column selection, chromatographic behaviour, troubleshooting and method performance.

Aastrinz supports laboratories with application guid­ance, product selection, method-development assistance, troubleshooting and HPLC column training. Its technical team works with customers facing issues such as peak performance, injection consistency and column suitability, while its application experience helps recommend solutions for established analytical methods.

Requirements also vary by industry. Pharmaceutical laboratories emphasize reproducibility, quality control and regulatory requirements, while research laboratories require flexibility as methods evolve. Food, chemical and healthcare laboratories may prioritize speed, reliability, application suitability and cost efficiency.

“Aastrinz’s approach is therefore application-led. Instead of treating a column as a standardized commodity, our team seeks to understand factors such as required chemistry, expected peak characteristics, method conditions and desired column life before recommending a solution”, adds Rajasekhar Reddy.

Supporting this model is a team across technical support, R&D, marketing, quotations, finance, administration, billing and dispatch. S.K. Verma looks after Business Development, including customer relationships and business expansion, supporting Aastrinz’s efforts to deepen its market presence. Leadership also remains directly involved in customer and product-development activities, helping laboratory feedback reach technical and R&D teams quickly.

Chromatography remains the strategic centre of Aastrinz’s business, with PURSIL HPLC Columns serving as one of its flagship offerings

Er. Aryan Batra, Managing Director

R&D and AI as the Next Layer of Laboratory Innovation

As laboratories become increasingly digital, Aastrinz sees artificial intelligence as a forward-looking area of exploration and development rather than a commercially deployed technology within its current portfolio. AI is creating possibilities across intelligent data analysis, predictive maintenance, automated method optimization and experimental design.

For Aastrinz, potential applications being explored include analytical workflows, method development, technical support, process automation and operational efficiency. The objective is to understand where AI can reduce manual effort, development time and cost without compromising analytical quality or compliance.

The company views AI as an enabler of scientific capability rather than a replacement for technical expertise. In a field where analytical decisions have direct quality implications, domain knowledge and technology must ultimately work together.

Taking Indian Chromatography to a Wider Market

Aastrinz’s roadmap is built around specialization rather than diversification for its own sake. Its priorities include strengthening the PURSIL HPLC Column portfolio, including continued development of CST, expanding its syringe filter range, introducing advanced analytical solutions and investing in chromatography R&D.

The company is simultaneously pursuing a broader pan-India expansion strategy across major pharmaceutical and industrial clusters. Its growing presence includes Hyderabad, Bengaluru, Gujarat, Maharashtra, Baddi and other parts of Himachal Pradesh, Chandigarh, Dehradun and Haridwar. Strengthening its dealer and distributor network will be an important part of this national expansion.

International markets represent the larger long-term ambition. Aastrinz is working towards developing international partnerships and taking PURSIL HPLC Columns and its broader chromatography solutions to laboratories beyond India. Its vision is to establish Aastrinz as a trusted global chromatography and analytical laboratory solutions brand.

For decades, Indian laboratories have depended on international manufacturers for many high-value analytical and chromatography products. Aastrinz wants to participate in changing that equation by demonstrating the capabilities of an Indian chromatography brand supported by technical expertise, application knowledge and responsive customer engagement.

The journey, therefore, is about more than expanding a product catalogue. It is about building credibility around PURSIL, strengthening technical capabilities and developing a company laboratories associate with reproducibility, responsive support and application expertise. With chromatography firmly at the strategic centre of its business, Aastrinz is building around PURSIL through complementary syringe filtration, sample preparation and broader analytical laboratory solutions.

As analytical science moves toward faster, smarter and increasingly automated workflows, Aastrinz Life Sciences is betting that focused innovation, technical expertise and enduring customer relationships can give an Indian chromatography brand a meaningful place on the global laboratory map.
 

Aastrinz Life Sciences’ Competitive Edge

  • Strong specialization in chromatography and analytical solutions
  • PURSIL HPLC Columns designed for reliable and reproducible performance
  • PURSIL HPLC Columns manufactured under the technical guidance of G. Rambabu
  • CoroShield Technology (CST) supporting expansion of the PURSIL portfolio
  • Trial columns and in-house application and sample testing capabilities in Hyderabad
  • Dedicated technical, troubleshooting and method-development support
  • Integrated portfolio spanning HPLC columns, syringe filters and sample preparation
  • Pan-India expansion and long-term international growth vision

on the deck


Most Viewed

Addressing Antimicrobial Resistance (AMR) Through Collaborative Efforts Fostering a Quality Culture in the Pharmaceutical Industry Advancements in Computer-Aided Drug Design for Pharmaceutical Research Why India is Gaining Popularity for Clinical Trials The Future of Kidney Transplants in India Usage of Conversational AI in the Health Insurance Sector Strategies for India to Reduce Its API Dependence on China Business Impact of USFDA Approvals on Indian Pharma Companies Innovative Strategies for Expanding Access to Life Saving Healthcare Solutions Badhal Village Crisis: How Rapid Diagnostics Could Have Saved Lives Why India is a Hotspot for Biotech Startups? Why Adapting Flexibility in IP Rights will Drive Generics Market Meeting the Challenges of High-Potency API (HPAPI) Production Impact of Human Factors Engineering on Medical Device Safety The Future of Pharma: Embracing Continuous Manufacturing The Role of Orphan Drugs in Treating Rare Diseases Emerging Technologies Shaping the Future of Drug Formulation Strategies for Optimizing Pharmaceutical Supply Chain Efficiency The Future of Medicine: Harnessing the Power of RNA-based Therapeutics AI in Medicine: Unmasking the Myths and Embracing the Transformative Reality Cycle Pharma Acquires Banner Life Sciences WHO's First-ever Global Summit on Traditional Medicine Starts in Gujarat The Importance of Data Integrity in Pharmaceutical Quality Control DCGI in Talks with Stakeholders to Develop a Standardised Web Platform to Assure Drug Quality and Patient Safety Glenmark Pharmaceuticals secures ANDA Nod for 0.03 per cent Tacrolimus Ointment Streamlining Laboratory Operations with a Modern LIMS Healthtech Start-up Suraksha QR Ropes In Actor Murali Sharma as its Brand Ambassador Unlocking the Potential of Pharmacogenomics: Enhancing Drug Safety and Efficacy The Impact of Pharmaceutical Testing on Drug Development India has Identified Three Health Priorities to Strengthen Global Health Infrastructure, says WHO National Health Authority launches 100 Microsites Project to Speed Up Digital Health Adoption India Should Partner with Australia to avail PBS for the Selection, Listing, and Pricing processes of exported drugs, says Sudarshan Jain Zydus Lifesciences India More than Doubles Profit Due to Increased Sales in the US India Triples Organ Donations over Past Decade says Union health minister Mansukh Mandaviya Advent Therapeutics Awarded $3 Million NIH Grant For Novel Neonatal Lung Therapy Three Pharma Marketing Strategies That Drive Sales Novartis Targets India's Rare Disease Market with 17 Clinical Programs UK Health Regulator approves GSK's Vaccine for the common respiratory virus RSV WHO Urges Increased Use Of Recommended Malaria-Fighting Tools Karnataka Budget Offered a Significant Boost to Health & Lifesciences Start-ups with Focus on Infrastructure & Innovation Three High Potential Moonshot Project Areas in Pharma CCI approves Bharat Biotech International-Eastman Exports deal How Biotech is Revolutionizing the Fight Against Cancer LifeCell and HaystackAnalytics ink strategic pact to scale-up TB whole genome sequencing pan-India Mankind Pharma IPO To Open On April 25 With A Price Fixed At Rs 1,026-1,080 Per Share US CDC Approves Second Omicron-Updated COVID Booster For Adults Three Trends that will Impact Pharmaceutical Industry in 2023 ModeX Therapeutics Commences Phase I EBV Vaccine Trial with Merck Designing Impactful Leadership and Talent Management Programs with Strategies for Success Novo Nordisk and Valo Health Partner to develop novel Treatments FOPE Calls for Extended Deadline for Schedule M Compliance Telix Pharma To Acquire ImaginAb to Boost Therapeutics and Innovation Roche Secures US FDA Approval for its Ultra-Sensitive ISH test Rappta Therapeutics and SpringWorks Partner on Molecular Glue Targeting PP2A Taro Pharma To Acquire entire stake in Antibe Therapeutics Innovent Biologics Secures Breakthrough Therapy Designation for IBI343 Emcure Pharma Launches Largest R&D Centre in Ahmedabad Zydus Bags USFDA Nod for Phase II(b) Trial to Optimize Usnoflast Dosage US FDA Approves Amgen's Lumakras-Vectibix Combo for KRAS G12C-Mutated mCRC Glenmark Pharma Unveils generic anticoagulant injectable emulsion Strides Pharma Bags USFDA Nod for OTC Acetaminophen-Ibuprofen Combo Tablets US FDA Lifts Hold on Sanofi's Trial to Make Cialis Available Over-the-Counter Hoth Therapeutics Expands Intellectual Property with New Patents Jaguar Health Starts POC Trial of Crofelemer for Rare Pediatric Disease MVID Pharma and Healthcare Sector Eyes Union Budget 2025 for Innovation Boost How Innovative Drug Formulations are Enhancing Treatment Outcomes Apollo and Mayapada Healthcare Unite to Boost Indonesia's Healthcare Novo Nordisk Reports Positive Phase 1b/2a Results for Amycretin Govt to Extend Schedule M Compliance Deadline for Drug Manufacturers to Dec Lupin Secures US FDA Nod for Ipratropium Bromide Nasal Solution ANDA Granules Pharmaceuticals Secures USFDA Nod for Key Generic Drug Bajaj Healthcare Bags DCGI Nod to Manufacture Pimavanserin API & Formulation Union Budget 2025: Healthcare Gets 9.78% Boost, Allocation Nears 1 Lakh Crore Metropolis & Roche Launch Self-Sampling HPV Test for Cervical Cancer Sigachi Industries Invests $1M in Hyderabad R&D Hub for API Innovation Pharma Testing Market Surges with Rising Demand for Biologics ISTH Releases Clinical Practice Guideline For Haemophilia Treatment Sanofi and Biovac Lead Polio Vaccine Manufacturing Capabilities Sun Pharma and Takeda Ink Pact To Market Gastrointestinal Drug Takeda and Ascentage Pharma Ink Option Agreement For Olverembatinib Enhancing Compliance through Effective Pharmaceutical Regulatory Affairs Strategies India poised to become a Global Hub for Clinical Trials: Exec SCHOTT Pharma Unveils Next-Gen Polymer Syringes for Enhanced Safety GSK's Jemperli Gains EU Nod for First-Line Treatment of Endometrial Cancer Union Health Secretary Urges Stronger Drug Regulations for Quality Control Telangana Govt Inks Landmark Deals to Propel Life Sciences and Job Growth R&D in Indian Pharma: Breakthroughs and Innovations in 2024 Dr. Reddy's Partners with Shanghai Henlius to Develop Cancer Drug Uniphar Expands Global Footprint with Three New Facilities 74th Indian Pharmaceutical Congress 2025 Opens Registrations AGC Pharma Expands HPAPI Capabilities in Barcelona to Meet Growing Demand The Future of Genomic Sequencing: Trends That Will Define the Next Decade Lexaria Bioscience Ethics Review Board Nod to Commence New GLP-1 Study Amitabh Kant Urges India to Focus on Innovation at BioAsia 2025 Government Enhances Research & Integration Initiatives in Unani Medicine Blind & Deaf individuals face Major Barriers to access Medicines: Report C-CAMP and PariSante Campus launched Indo-French Life Sciences Hub Jaguar Health Begins Pediatric Trial for Crofelemer in Short Bowel Syndrome Algiax Pharma Reports Promising Phase 2a Results for AP-325 Govt Bans 34 Antimicrobials for Use in Animals Pharmaceutical Procurement Strategies: How to Optimize Costs Personalized Medicine: Get Tailored Treatment Plans for You Now How to Bridge the Healthcare Gap in Emerging Markets with MedTech The Evolution of In-Vitro Diagnostics: Trends and Future Prospects Needle-Free Injection System: A Game Changer in Less Pain Vaccination How Global Capability Centers are Shaping the Future of Biometrics Building a Successful Pharma Brand in India: The Role of Scientific Communication Unlocking India's Innovation Potential in Pharma The Future of Green Chemistry in API Production Top 10 Pharmaceutical Recruitment Consultants - 2024 | Pharma Outlook Blockchain for Secure Pharmaceutical Supply Chains - 2025 & Beyond Mass Spectrometry in Biomarker Discovery for Early Disease Detection Iconovo and Lonza Team up to Advance Intranasal Biologic with ICOone Nasal Fetal Imaging to Cardiac Diagnosis: The Expanding Role of Ultrasound Balancing Innovation and Affordability in Medical Solutions for India Changing Landscape for LTBI and Syndromic Testing Methodologies How Advanced Training Methods can Enhance Patient Care Balancing Cost Efficiency and Compliance in Pharmaceutical Manufacturing LUB Urges Govt to Scrap Mandatory Lab Testing for Cough Syrup Exports Role of Optical Imaging in Early Cancer Detection and Treatment Hoth Therapeutics Unveils Promising Data for KIT-Targeting Therapy Pharmexcil Engages ASEAN Nations to Boost Pharma Trade Ties Fortis Partners with Teleflex for South Asia UroLift Training Anti-Infectives: How New Research is Shaping Infection Control Building Bridges for Sustainable Growth through Strategic Alliances in Ethical Pharmaceuticals Quality as the Cornerstone of Lab Solutions FDA Approves Roch's NSCLC Diagnostic Linked to Emrelis How Early Detection is Transforming Cancer Treatment in India Ensuring Data Privacy in Pharma World Enhancing Clinical Trial Supply Chain Resilience to Address Global Disruptions in India Cost-Effectiveness of Minimally Invasive Surgery in Outpatient Settings How Organic Synthesis is Accelerating Drug Discovery in Pharma Strategic finance for pharmaceutical innovation and stability Top 10 Teleradiology Service Providers - 2024 | Pharma Outlook Importance of Investing in R&D and Quality for Competitive Advantage in Eye Care Top 10 In Vitro Diagnostics Companies - 2024 | Pharma Outlook Phytopharmaceuticals: Driving Global Herbal Medicine Innovation Gender Gap in Healthcare: Why Women's Health Needs More Research Impact of Modern Technology on the Indian Life Sciences Sector Why Global Pharma Expects CDMOs to Be Ready for Joint Inspections The Role of Customizable Stent Grafts for Treating Complex Anatomies Nutraceuticals vs Pharmaceuticals: Complementary or Alternative in Chronic Disease Management? Top 10 Pharma CDMO Companies In India – 2023 | Pharma Outlook Leaping Towards Global Compliance with Revised Schedule M Meril Concludes TechVentory, Boosts AI-Driven Healthcare Supply Chains 10 Pharma Sector Revolutions in India Standardizing Medicine Labeling and Embracing Digital Transformation Creating a patient-centric healthcare ecosystem for all Biomanufacturing of Enzymes: A Sustainable Approach to Industrial Biotechnology Integrating CSR into HR Practices to Enhance Brand Reputation in Pharma Merck Launches Phase 3 Trial for Promising Dengue Vaccine V181 Breakthrough: Eye-Opening Healthcare Strategies Doctors Swear By on Doctor's Day 2025 Bristol Myers Squibb Reports Strong Phase 3 Results for Deucravacitinib trail Alcon Launches Innovative Daily Lenses Designed for Long-lasting Comfort Apisolex Excipient by Lubrizol Backs Phase I Drug Success FDA Approves Enflonsia to Prevent RSV in Infants with One Dose Biosimilars in India 2025 Market Trends, Growth Forecast & Opportunities How Regulations Are Shaping India's Medical Device Landscape Bharat Biotech Partners with GSK for Shigella Vaccine Development Eli Lilly Obesity Drug Shows 11.5% Weight Loss in 12 Weeks Laborate Pharmaceuticals: Illuminating Pathways Of Quality, Affordability Innovation In Healthcare Sun Pharma Bags CDSCO Approval to Produce Fexuprazan Hydrochloride Tablets The Fusion of Biology, Medicine, Health, and AI Glenmark Gets DCGI Nod to Launch Oncology Drug BRUKINSA in India Kyndryl Partners with Dr Reddys to Automate Global IT Operations How Robotic Assisted Surgery Is Redefining Precision in Kidney Transplants Top 10 Women Disruptors in Asia Pharmaceutical Industry

© 2026 India Pharma Outlook. All Rights Reserved.